Xencor Inc (XNCR) FinancialsXNCRFinancialXencor Inc

Xencor, Inc. (XNCR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Royalties, accounting for 80.5% of total sales, equivalent to $41.22M. Another important revenue stream is Milestone. Understanding this composition is critical for investors evaluating how XNCR navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Xencor, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -71.45%, while the net margin is -42.42%. These profitability ratios, combined with a Return on Equity (ROE) of -29.07%, provide a clear picture of how effectively XNCR converts its operational activities into shareholder value.

In the context of the broader market, XNCR competes directly with industry leaders such as ALVO and GENB. With a market capitalization of $1.94B, it holds a significant position in the sector. When comparing efficiency, XNCR's gross margin of 100.00% stands against ALVO's 50.71% and GENB's 100.00%. Such benchmarking helps identify whether Xencor, Inc. is trading at a premium or discount relative to its financial performance.

Xencor's revenue growth is notable, with Q2 2026 revenue at $51.22 million, surpassing expectations. However, the company is still operating at a loss, with a net income of -$128.92 million in Q1 2026.